Blog

Why Spark’s CEO says 2017 may be a ‘historic year’ for his gene therapy company – Philadelphia Business Journal


Philadelphia Business Journal

Why Spark's CEO says 2017 may be a 'historic year' for his gene therapy company
Philadelphia Business Journal
Philadelphia gene therapy company Spark Therapeutics said it is in the final stages of completing its rolling biologics license application for its lead product: a one-time treatment for an inherited retinal disease that causes blindness in children
Spark Therapeutics Reports 2016 Financial Results and Business HighlightsGlobeNewswire (press release)



all 2 news articles »

2017-02-22 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.